WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing. The vaccine is produced by the Beijing-based pharmaceutical company Sinovac. Africa urgently needs 20 million second doses of COVID-19 vaccine
Africa needs at least 20 million doses of the Oxford-AstraZeneca vaccine in the next six weeks to get second doses to all who received a first dose within the 8 - 12-week interval between doses recommended by the World Health Organization (WHO). 60 million doses of COVID-19 vaccine administered in UK
WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations
WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG). First COVID-19 COVAX vaccine doses administered in Africa
The AMC is the COVAX Facility’s mechanism to provide donor-funded vaccines to lower-income countries.
COVAX announces new agreement, plans for first deliveries
More Pharma News ...
Business & Industry
- Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
- Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer
- Petrovax Pharm is taking part in the international pharmaceutical exhibition CPhI Worldwide-2021
- Roche's anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's disease
- Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations
Research & Development
- Common antidepressant should no longer be used to treat people with dementia
- High effectiveness of mix-and-match COVID-19 vaccines
- One coronavirus vaccine may protect against other coronaviruses
- Vaccines effective against most SARS-CoV-2 variants
- Scientists discover a highly potent antibody against SARS-CoV-2
- mRNA COVID vaccines highly effective at preventing symptomatic infection in health workers
- How to develop new drugs based on merged datasets
Conferences & Events
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
Regulatory Affairs
- FDA takes additional actions on the use of a booster dose for COVID-19 vaccines
- FDA awards 11 grants to clinical trials to develop new medical products for rare disease treatments
- FDA approves innovative treatment for pediatric patients with congenital athymia
- FDA authorizes software that can help identify prostate cancer
- FDA advances data, IT modernization efforts with new office of digital transformation